Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Update on study 006--EFV + AZT + 3TC versus the current 'standard of care' IDV + AZT + 3TC.

Int J Clin Pract Suppl. 1999 Jun;103:10-5. Unique Identifier : AIDSLINE MED/20087917
Staszewski S; Johann Wolfgang Goethe-University, Frankfurt am Main, Germany.

Abstract: Study 006 is a pivotal Phase III, multicentre, randomized, open-label study designed to compare the antiretroviral activity and tolerability of efavirenz (EFV) + zidovudine (AZT) + lamivudine (3TC) with indinavir (IDV) + AZT + 3TC and EFV + IDV. Using both the 'observed data' analysis and intent-to-treat non-completer = failure analysis, the results at 48 weeks showed that efavirenz, in combination with AZT + 3TC was superior to IDV + AZT + 3TC. EFV + AZT + IDV was shown to be equally effective in patients with high and low baseline viral loads. Toxicities resulting in premature discontinuations were 3-fold higher in the IDV + AZT + 3TC arm than in both efavirenz-containing arms. Preliminary results suggested that efavirenz increased high density lipid (HDL) levels but the clinical significance of this observation is unknown. The results from Study 006 indicate that the combination EFV + AZT + 3TC is a highly active protease inhibitor-sparing regimen for first-line treatment of HIV-infected patients.

Keywords: CLINICAL TRIAL CLINICAL TRIAL, PHASE III JOURNAL ARTICLE MULTICENTER STUDY RANDOMIZED CONTROLLED TRIAL Acquired Immunodeficiency Syndrome/*DRUG THERAPY/VIROLOGY Anti-HIV Agents/ADVERSE EFFECTS/*THERAPEUTIC USE Drug Therapy, Combination Human Indinavir/THERAPEUTIC USE Lamivudine/THERAPEUTIC USE Lipids/METABOLISM Oxazines/ADVERSE EFFECTS/*THERAPEUTIC USE Viral Load Zidovudine/THERAPEUTIC USE

KWDclinicaltrialclinicaltrial,phaseiiijournalarticlemulticenterstudyrandomizedcontrolledtrialacquiredimmunodeficiencysyndrome/KWDdrugtherapy/virologyanti-hivagents/adverseeffects/KWDtherapeuticusedrugtherapy,combinationhumanindinavir/therapeuticuselamivudine/therapeuticuselipids/metabolismoxazines/adverseeffects/KWDtherapeuticuseviralloadzidovudine/therapeuticuse
000430
A0040890

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .